Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 7, 2012, Pages 2521-2526

  Fang, Hai Tong ^a,b   Zhang, Bo ^a,b   Pan, Xiao Fen ^c   Gao, Li ^d   Zhen, Tao ^c,e,f   Zhao, Hong Xia ^g   Ma, Liang ^a,f   Xie, Jun ^c   Liu, Zi ^a   Yu, Xian Jun ^a,e   Cheng, Xin ^a   Feng, Ting Ting ^c,f   Zhang, Feng Xiang ^c   Yang, Yong ^c   Hu, Zhong Guo ^c   Sheng, Guo Qing ^c   Chen, Yong Long ^c   Chen, Sai Juan ^e   Chen, Zhu ^e   Zhou, Guang Biao ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^g Second Artillery General Hospital   (China)

Author keywords

Apoptosome; Internalization; Proteolysis; Stem cell factor receptor

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BORTEZOMIB; CASPASE 3; HEAT SHOCK PROTEIN 90; HYBRID PROTEIN; IMATINIB; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ENDOCYTOSIS; GASTROINTESTINAL STROMAL TUMOR; INTERNALIZATION; LEUKEMIA CELL; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TUMOR CELL;

APOPTOSIS; BORONIC ACIDS; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; HUMANS; LEUKEMIA; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-KIT; PYRAZINES; TRANSLOCATION, GENETIC;

MUS;

EID: 84863116492     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1121341109     Document Type: Article

References (35)

1. Yarden Y, et al. (1987) Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341-3351.
2. Toffalini F, Demoulin JB (2010) New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 116:2429-2437.
3. Miyazawa K, et al. (1994) Ligand-dependent polyubiquitination of c-kit gene product: A possible mechanism of receptor down modulation in M07e cells. Blood 83:137-145. (Pubitemid 24016525)
4. Gommerman JL, Rottapel R, Berger SA (1997) Phosphatidylinositol 3-kinase and Ca2+ influx dependence for ligand-stimulated internalization of the c-Kit receptor. J Biol Chem 272:30519-30525. (Pubitemid 27512265)
5. Masson K, Rönnstrand L (2009) Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal 21:1717-1726.
6. Miettinen M, Lasota J (2005) KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 13:205-220. (Pubitemid 41209013)
7. Hirota S, et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580. (Pubitemid 28067289)
8. Wang YY, et al. (2005) AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 102:1104-1109.
9. Erickson P, et al. (1992) Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80:1825-1831.
10. Yan M, et al. (2006) A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 12:945-949. (Pubitemid 44175147)
11. Jiao B, et al. (2009) AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 23:1598-1604.
12. Wang YY, et al. (2011) C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 108:2450-2455.
13. Zheng X, Oancea C, Henschler R, Ruthardt M (2009) Cooperation between constitutively activated c-Kit signaling and leukemogenic transcription factors in the determination of the leukemic phenotype in murine hematopoietic stem cells. Int J Oncol 34:1521-1531.
14. Kelly LM, Gilliland DG (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3:179-198. (Pubitemid 35217435)
15. Lin P, et al. (2008) Acute myeloid leukemia harboring t(8;21)(q22;q22): A heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Mod Pathol 21:1029-1036.
16. Marcucci G, et al. (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 23:5705-5717.
17. Kuwatsuka Y, et al. (2009) Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood 113:2096-2103.
18. Ciechanover A (2005) Proteolysis: From the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6:79-87.
19. Hideshima T, et al. (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114:1046-1052.
20. Sun XM, et al. (2004) Caspase activation inhibits proteasome function during apoptosis. Mol Cell 14:81-93.
21. Macia E, et al. (2006) Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell 10:839-850. (Pubitemid 43779110)
22. Tuveson DA, et al. (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 20:5054-5058. (Pubitemid 32769795)
23. Broudy VC, et al. (1999) Signaling via Src family kinases is required for normal internalization of the receptor c-Kit. Blood 94:1979-1986. (Pubitemid 29430414)
24. Kurokawa M, Zhao C, Reya T, Kornbluth S (2008) Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. Mol Cell Biol 28:5494-5506.
25. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537-549.
26. Pandey P, et al. (2000) Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 19:4310-4322. (Pubitemid 30623742)
27. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X (1997) Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413. (Pubitemid 27347231)
28. Huang Q, et al. (2011) Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 17:860-866.
29. Zhou GB, et al. (2007) Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 109:3441-3450.
30. Zhou GS, et al. (2011) Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Leuk Res 35:214-218.
31. Kozu T, Fukuyama T, Yamami T, Akagi K, Kaneko Y (2005) MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21). Genes Chromosomes Cancer 43:45-53. (Pubitemid 40490354)
32. Zeng S, Xu Z, Lipkowitz S, Longley JB (2005) Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood 105:226-232. (Pubitemid 40053087)
33. Harir N, et al. (2008) Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 112:2463-2473.
34. Amaravadi R, Thompson CB (2005) The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115:2618-2624. (Pubitemid 41434384)
35. Wichmann C, et al. (2007) Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Cancer Res 67:2280-2289. (Pubitemid 46424248)